leveraging its proprietary technology platforms, alphamab oncology has developed an exciting portfolio of pipelines with clear differentiation and global competitiveness. with clinically proven targets, cmc-validated manufacturing and global ip rights, alphamab oncology has created well-rounded pipeline projects with low risk and superb upside potential.
recent progress in cancer immunotherapy has marked a historic breakthrough. at alphamab oncology, we have developed not only a well differentiated pd-l1 antibody (kn035), but also a potential backbone of next generation immuno-oncology therapy (kn046), representing a leap forward from currently available drugs on the market or in development.
several other bispecific programs with best-in-class or first-in-class potential are also under development.
